nitroaspirin

Nitroaspirin is a nitric oxide (NO)-donating derivative of acetylsalicylic acid (aspirin), designed to combine the anti-inflammatory, analgesic, antipyretic, and antithrombotic properties of aspirin with the gastroprotective and vasodilatory effects of nitric oxide. The drug acts as a direct and irreversible inhibitor of cyclooxygenase (COX), particularly COX‑1, thereby reducing prostaglandin and thromboxane synthesis. This results in anti-inflammatory effects as well as inhibition of platelet aggregation. The NO-donating moiety is intended to protect the gastric mucosa from damage typically associated with traditional NSAIDs by modulating prostaglandins and providing additional vascular benefits. Nitroaspirin has been investigated for indications such as intermittent claudication, peripheral arterial occlusive disease, type 2 diabetes mellitus, pain management, and has also shown potential immunomodulatory activity in cancer models by correcting immune dysfunction in tumor-bearing hosts[1][3][4][5].

Other names

nitroaspirinnitric oxide-releasing aspirin2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester[3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoatebenzoic acid, 2-(acetyloxy)-, 3-(nitrooxymethyl)phenyl ester